Enanta Pharmaceuticals | ENTA - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 7.61B 2.04B 2026-06
Amgen USD 2.08B 570M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
AstraZeneca USD 4.81B 894M 2026-06
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 647.3M 269.6M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -19.3M 6.28M 2025-12
Incyte USD 751.51M 407.91M 2026-06
Insmed USD -11.37M 150.72M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
J&J USD 8.66B 839M 2026-06
Karyopharm Therapeutics USD -22.39M 17.51M 2026-03
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
Merck USD -3.53B 6.95B 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06